Androgen Deprivation Therapy Market expected to reach $11.1 billion by 2030 at 5.9% CAGR

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Androgen Deprivation Therapy Market Evolve From 2026 To 2030?

The market size for androgen deprivation therapy has experienced substantial growth in recent years. It is projected to expand from $8.31 billion in 2025 to $8.83 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.3%. This expansion during the historic period can be attributed to factors such as limited treatment options for prostate cancer, a reliance on conventional surgery, the slow adoption of injectable therapies, low patient awareness of androgen deprivation therapy, and restricted availability of advanced therapies.

The androgen deprivation therapy market is projected to experience substantial growth over the next few years, with its size expected to reach $11.1 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 5.9%. This expansion during the forecast period can be attributed to the development of innovative anti-androgen drugs, increasing investments in gene and immunotherapies, a rising geriatric male population, the proliferation of specialty clinics and hospital oncology departments, and the integration of digital monitoring and telehealth solutions. Significant trends anticipated in this period include the escalating adoption of LHRH agonists and antagonists, enhanced use of combination and targeted therapies, the expansion of minimally invasive surgical procedures, a heightened focus on patient-specific and age-based treatments, and improved monitoring and follow-up care for prostate cancer patients.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=25692&type=smp

What Major Drivers Are Influencing Demand In The Androgen Deprivation Therapy Market?

The rising occurrence of prostate cancer is anticipated to stimulate expansion in the androgen deprivation therapy market over the next few years. This malignancy develops within the prostate gland, an organ in the male reproductive system crucial for seminal fluid production. The climb in its prevalence is largely attributable to extended human lifespans, given that advanced age substantially elevates the likelihood of acquiring this condition. Androgen deprivation therapy (ADT) serves as a key treatment approach for prostate cancer, designed to reduce androgen levels which promote tumor proliferation. This therapy is often employed in advanced or metastatic phases to slow down the advancement of the disease. As an illustration, in January 2025, data from a report issued by Prostate Cancer UK, a UK-based organization dedicated to prostate cancer research, awareness, and support, showed that in England, prostate cancer diagnoses grew from 50,751 cases in 2022 to 55,033 cases in 2023, demonstrating a distinct increase in annual frequency. Consequently, the growing occurrence of prostate cancer is propelling the expansion of the androgen deprivation therapy market.

Which Segment Areas Are Covered In The Androgen Deprivation Therapy Market Analysis?

The androgen deprivation therapy market covered in this report is segmented –

1) By Type: Medicine, Surgery, Other Types

2) By Route Of Administration: Injectable, Oral

3) By Patient Demographics: Men Aged 40-60, Men Aged 61-75, Men Above 75

4) By Application: Prostate Cancer, Other Applications

5) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Medicine: LHRH Agonists, LHRH Antagonists, Anti-Androgens, CYP17 Inhibitors, Steroidal Anti-Androgens, Non-Steroidal Anti-Androgens, Estrogen-Based Therapies, Combination Therapies

2) By Surgery: Bilateral Orchiectomy, Subcapsular Orchiectomy, Simple Orchiectomy

3) By Other Types: Radiopharmaceutical Therapy, Gene Therapy, Immunotherapy, Targeted Therapy, Cryotherapy, High-Intensity Focused Ultrasound (HIFU

What Key Developments And Trends Are Impacting The Androgen Deprivation Therapy Market?

Leading companies within the androgen deprivation therapy (ADT) market are concentrating on creating sophisticated solutions, including oral androgen receptor inhibitors (ARIs), to deliver more accessible, manageable, and potent treatment choices for individuals with prostate cancer. Oral ARIs represent targeted treatments that directly impede androgen receptor activity in prostate cancer cells, thereby preventing tumor development without necessitating frequent clinic-administered hormone-suppressing injections. For example, in June 2025, Bayer AG, a multinational pharmaceutical entity from Germany, secured US Food and Drug Administration (FDA) approval for Nubeqa (darolutamide), an oral ARI prescribed alongside ADT for managing metastatic hormone-sensitive prostate cancer (mHSPC). Intended to elevate clinical achievements and patient well-being, Nubeqa suppresses androgen receptor signaling with high binding affinity, displays minimal blood–brain barrier penetration to reduce central nervous system side effects, and demonstrated a 46% reduction in the likelihood of radiological progression or death when contrasted with a placebo plus ADT, according to the Phase III ARANOTE trial.

Which Global Companies Are Actively Competing In The Androgen Deprivation Therapy Market?

Major companies operating in the androgen deprivation therapy market are Johnson & Johnson Services Inc., Astellas Pharma Inc., Ipsen S.A., Ferring Pharmaceuticals SA, Tolmar Pharmaceuticals Inc., Pfizer Inc., Novartis AG, Dr. Reddy’s Laboratories Ltd., Orion Corporation, Besins Healthcare S.A., Veru Inc., Kintor Pharmaceutical Limited, Foresee Pharmaceuticals Co. Ltd., Lawley Pharmaceuticals Pty Ltd., AbbVie Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Lupin Limited, Cipla Ltd., Accord Healthcare Ltd., Mylan N.V. (Viatris), Zydus Lifesciences Ltd., Apotex Inc., Amneal Pharmaceuticals LLC, Glenmark Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Torrent Pharmaceuticals Ltd., Aurobindo Pharma Ltd., Alvogen Inc., BCN Peptides SA, Chugai Pharmaceutical Co. Ltd., Sumitomo Pharma Co. Ltd.

Read the full androgen deprivation therapy market report here:

https://www.thebusinessresearchcompany.com/report/androgen-deprivation-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Growth In The Androgen Deprivation Therapy Market?

North America was the largest region in the androgen deprivation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the androgen deprivation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Androgen Deprivation Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=25692&type=smp

Browse Through More Reports Similar to the Global Androgen Deprivation Therapy Market 2026, By The Business Research Company

Hormone Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/hormone-therapy-global-market-report

Testosterone Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/testosterone-replacement-therapy-global-market-report

Drugs For Hormonal Replacement Therapy Market Report 2026

https://www.thebusinessresearchcompany.com/report/drugs-for-hormonal-replacement-therapy-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795